3'-O-MethylmurraolCAS# 1891097-17-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1891097-17-8 | SDF | Download SDF |
PubChem ID | 102337145 | Appearance | Powder |
Formula | C16H18O4 | M.Wt | 274.31 |
Type of Compound | Coumarins | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 7-methoxy-8-[(E)-3-methoxy-3-methylbut-1-enyl]chromen-2-one | ||
SMILES | CC(C)(C=CC1=C(C=CC2=C1OC(=O)C=C2)OC)OC | ||
Standard InChIKey | PVBOJBJEDABADF-MDZDMXLPSA-N | ||
Standard InChI | InChI=1S/C16H18O4/c1-16(2,19-4)10-9-12-13(18-3)7-5-11-6-8-14(17)20-15(11)12/h5-10H,1-4H3/b10-9+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. 3'-O-Methylmurraol exhibits inhibition (IC50 ≤ 7.31 ug/mL) of superoxide anion generation by human neutrophils in response to formyl-l-methionyl-l-leucyl-l-phenylalanine/cytochalasin B (fMLP/CB), it may have potential anti-inflammatory activity . |
Targets | Immunology & Inflammation related |
3'-O-Methylmurraol Dilution Calculator
3'-O-Methylmurraol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.6455 mL | 18.2276 mL | 36.4551 mL | 72.9102 mL | 91.1378 mL |
5 mM | 0.7291 mL | 3.6455 mL | 7.291 mL | 14.582 mL | 18.2276 mL |
10 mM | 0.3646 mL | 1.8228 mL | 3.6455 mL | 7.291 mL | 9.1138 mL |
50 mM | 0.0729 mL | 0.3646 mL | 0.7291 mL | 1.4582 mL | 1.8228 mL |
100 mM | 0.0365 mL | 0.1823 mL | 0.3646 mL | 0.7291 mL | 0.9114 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Fas C- Terminal Tripeptide
Catalog No.:BCC1019
CAS No.:189109-90-8
- Bruceantinoside C
Catalog No.:BCN1166
CAS No.:112899-35-1
- Salmefamol
Catalog No.:BCC1919
CAS No.:18910-65-1
- Hulupinic acid
Catalog No.:BCN8019
CAS No.:1891-42-5
- Oroselol
Catalog No.:BCN3907
CAS No.:1891-25-4
- [Ala92]-p16 (84-103)
Catalog No.:BCC5837
CAS No.:189064-08-2
- NGB 2904
Catalog No.:BCC7435
CAS No.:189061-11-8
- Corynantheine
Catalog No.:BCN3746
CAS No.:18904-54-6
- 1-(4-Hydroxy-2,2-dimethylchroman-6-yl)ethanone
Catalog No.:BCN7710
CAS No.:1890153-71-5
- Melilotigenin C
Catalog No.:BCN1165
CAS No.:188970-21-0
- Cilengitide
Catalog No.:BCC3942
CAS No.:188968-51-6
- L 760735
Catalog No.:BCC7840
CAS No.:188923-01-5
- Naringin dihydrochalcone
Catalog No.:BCN2579
CAS No.:18916-17-1
- Tegaserod maleate
Catalog No.:BCC7955
CAS No.:189188-57-6
- Ro 48-8071 fumarate
Catalog No.:BCC5546
CAS No.:189197-69-1
- Helioxanthin
Catalog No.:BCC5413
CAS No.:18920-47-3
- KU14R
Catalog No.:BCC1685
CAS No.:189224-48-4
- Cleroindicin C
Catalog No.:BCN1167
CAS No.:189264-44-6
- Cleroindicin D
Catalog No.:BCN1168
CAS No.:189264-45-7
- Cleroindicin F
Catalog No.:BCN1169
CAS No.:189264-47-9
- Eucalyptolic acid
Catalog No.:BCN3246
CAS No.:189272-68-2
- Delafloxacin
Catalog No.:BCC1522
CAS No.:189279-58-1
- Isotanshinone IIB
Catalog No.:BCN2513
CAS No.:109664-01-9
- N-Caffeoyl-O-methyltyramine
Catalog No.:BCC8216
CAS No.:189307-47-9
New coumarins and anti-inflammatory constituents from the fruits of Cnidium monnieri.[Pubmed:24879527]
Int J Mol Sci. 2014 May 28;15(6):9566-78.
The fruit of Cnidium monnieri is commercially used as healthcare products for the improvement of impotence and skin diseases. Three new coumarins, 3'-O-methylmurraol (1), rel-(1'S,2'S)-1'-O-methylphlojodicarpin (2), and (1'S,2'S)-1'-O-methylvaginol (3), have been isolated from the fruits of C. monnieri, together with 14 known compounds (4-17). The structures of these new compounds were determined through spectroscopic and MS analyses. Compounds 1, 4-12, and 14-17 exhibited inhibition (IC50 = 7.31 microg/mL) of superoxide anion generation by human neutrophils in response to formyl-l-methionyl-l-leucyl-l-phenylalanine/cytochalasin B (fMLP/CB). Compounds 7, 9-11, 15, and 17 inhibited fMLP/CB-induced elastase release with IC50 values =7.83 microg/mL. This investigation reveals that bioactive isolates (especially 6, 7, 14, and 17) could be further developed as potential candidates for the treatment or prevention of various inflammatory diseases.